APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Live Biotherapeutic Products (LBP) and Microbiome CDMO Service

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Outlook and Growth Opportunities 2026

5 June 2026193 pages

Choose your research edition.

Industry ResearchLive Biotherapeutic Products (LBP) and Microbiome CDMO Service Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Analysis and Forecast 2026-2032259 pages · $4,950 USD

Market perspective

The global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Live Biotherapeutic Products (LBP) and Microbiome CDMO Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Live Biotherapeutic Products (LBP) and Microbiome CDMO Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Live Biotherapeutic Products (LBP) and Microbiome CDMO Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Live Biotherapeutic Products (LBP) and Microbiome CDMO Service market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Live Biotherapeutic Products (LBP) and Microbiome CDMO Service market include Lallemand Health Solutions, Wacker Chemie AG, Biose Industrie, List Biological Labs, Inc., NIZO, SGS (Quay Pharmaceuticals), Assembly Biosciences, Inc., Recipharm (Arranta Bio) and Bacthera (Novonesis+Lonza), among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Live Biotherapeutic Products (LBP) and Microbiome CDMO Service and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Live Biotherapeutic Products (LBP) and Microbiome CDMO Service revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service market.

Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Segment by Company

Lallemand Health Solutions

Wacker Chemie AG

Biose Industrie

List Biological Labs, Inc.

NIZO

SGS (Quay Pharmaceuticals)

Assembly Biosciences, Inc.

Recipharm (Arranta Bio)

Bacthera (Novonesis+Lonza)

Smaltis

Lonza

vermicon AG

Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Segment by Type

Solid Dosage Form

Liquid Dosage Form

Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Segment by Application

Digestive System Diseases

Immune System Diseases

Metabolic Diseases

Other

Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Live Biotherapeutic Products (LBP) and Microbiome CDMO Service key companies, revenue, market share, and recent developments.

3. To split the Live Biotherapeutic Products (LBP) and Microbiome CDMO Service breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Live Biotherapeutic Products (LBP) and Microbiome CDMO Service market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Live Biotherapeutic Products (LBP) and Microbiome CDMO Service significant trends, drivers, influence factors in global and regions.

6. To analyze Live Biotherapeutic Products (LBP) and Microbiome CDMO Service competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Live Biotherapeutic Products (LBP) and Microbiome CDMO Service and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Live Biotherapeutic Products (LBP) and Microbiome CDMO Service.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service industry.

Chapter 3: Detailed analysis of Live Biotherapeutic Products (LBP) and Microbiome CDMO Service company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Live Biotherapeutic Products (LBP) and Microbiome CDMO Service in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Live Biotherapeutic Products (LBP) and Microbiome CDMO Service in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Industry Trends Table 2. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Industry Drivers Table 3. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Industry Opportunities and Challenges Table 4. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Industry Restraints Table 5. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Share by Company (2021-2026) Table 7. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Key Company Manufacturing Base & Headquarters Table 9. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Company, Product Type & Application Table 10. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Solid Dosage Form Table 15. Significant Companies of Liquid Dosage Form Table 16. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type (2021-2026) Table 20. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Digestive System Diseases Table 22. Significant Companies of Immune System Diseases Table 23. Significant Companies of Metabolic Diseases Table 24. Significant Companies of Other Table 25. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application (2021-2026) Table 29. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application (2027-2032) Table 30. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Region (2021-2026) Table 33. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Region (2027-2032) Table 35. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Market Share by Country (2021-2026) Table 38. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Market Share by Country (2027-2032) Table 40. Lallemand Health Solutions Company Information Table 41. Lallemand Health Solutions Business Overview Table 42. Lallemand Health Solutions Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Lallemand Health Solutions Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio Table 44. Lallemand Health Solutions Recent Development Table 45. Wacker Chemie AG Company Information Table 46. Wacker Chemie AG Business Overview Table 47. Wacker Chemie AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Wacker Chemie AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio Table 49. Wacker Chemie AG Recent Development Table 50. Biose Industrie Company Information Table 51. Biose Industrie Business Overview Table 52. Biose Industrie Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Biose Industrie Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio Table 54. Biose Industrie Recent Development Table 55. List Biological Labs, Inc. Company Information Table 56. List Biological Labs, Inc. Business Overview Table 57. List Biological Labs, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. List Biological Labs, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio Table 59. List Biological Labs, Inc. Recent Development Table 60. NIZO Company Information Table 61. NIZO Business Overview Table 62. NIZO Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. NIZO Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio Table 64. NIZO Recent Development Table 65. SGS (Quay Pharmaceuticals) Company Information Table 66. SGS (Quay Pharmaceuticals) Business Overview Table 67. SGS (Quay Pharmaceuticals) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. SGS (Quay Pharmaceuticals) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio Table 69. SGS (Quay Pharmaceuticals) Recent Development Table 70. Assembly Biosciences, Inc. Company Information Table 71. Assembly Biosciences, Inc. Business Overview Table 72. Assembly Biosciences, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Assembly Biosciences, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio Table 74. Assembly Biosciences, Inc. Recent Development Table 75. Recipharm (Arranta Bio) Company Information Table 76. Recipharm (Arranta Bio) Business Overview Table 77. Recipharm (Arranta Bio) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Recipharm (Arranta Bio) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio Table 79. Recipharm (Arranta Bio) Recent Development Table 80. Bacthera (Novonesis+Lonza) Company Information Table 81. Bacthera (Novonesis+Lonza) Business Overview Table 82. Bacthera (Novonesis+Lonza) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Bacthera (Novonesis+Lonza) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio Table 84. Bacthera (Novonesis+Lonza) Recent Development Table 85. Smaltis Company Information Table 86. Smaltis Business Overview Table 87. Smaltis Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Smaltis Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio Table 89. Smaltis Recent Development Table 90. Lonza Company Information Table 91. Lonza Business Overview Table 92. Lonza Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 93. Lonza Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio Table 94. Lonza Recent Development Table 95. vermicon AG Company Information Table 96. vermicon AG Business Overview Table 97. vermicon AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 98. vermicon AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio Table 99. vermicon AG Recent Development Table 100. Research Programs/Design for This Report Table 101. Authors List of This Report Table 102. Secondary Sources Table 103. Primary Sources List of Figures Figure 1. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Image Figure 2. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021-2032) & (US$ Million) Figure 4. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Solid Dosage Form Image Figure 8. Liquid Dosage Form Image Figure 9. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type (2021-2032) Figure 12. Digestive System Diseases Image Figure 13. Immune System Diseases Image Figure 14. Metabolic Diseases Image Figure 15. Other Image Figure 16. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application (2021-2032) Figure 19. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value (2021-2032) & (US$ Million) Figure 22. North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value (2021-2032) & (US$ Million) Figure 28. South America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Solid Dosage Form
  • Liquid Dosage Form
Applications
  • Digestive System Diseases
  • Immune System Diseases
  • Metabolic Diseases
  • Other
Companies covered
  • Lallemand Health Solutions
  • Wacker Chemie AG
  • Biose Industrie
  • List Biological Labs, Inc.
  • NIZO
  • SGS (Quay Pharmaceuticals)
  • Assembly Biosciences, Inc.
  • Recipharm (Arranta Bio)
  • Bacthera (Novonesis+Lonza)
  • Smaltis
  • Lonza
  • vermicon AG

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Dynamics
  1. 2.1 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Industry Trends
  2. 2.2 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Industry Drivers
  3. 2.3 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Industry Opportunities and Challenges
  4. 2.4 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Industry Restraints
3 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market by Company
  1. 3.1 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Company Revenue Ranking in 2025
  2. 3.2 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Company (2021-2026)
  3. 3.3 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Company Ranking (2024-2026)
  4. 3.4 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Company Manufacturing Base and Headquarters
  5. 3.5 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Company Product Type and Application
  6. 3.6 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market by Type
  1. 4.1 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Type Introduction
  2. 4.1.1 Solid Dosage Form
  3. 4.1.2 Liquid Dosage Form
  4. 4.2 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value by Type
  5. 4.2.1 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value by Type (2021-2032)
  7. 4.2.3 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type (2021-2032)
5 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market by Application
  1. 5.1 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Application Introduction
  2. 5.1.1 Digestive System Diseases
  3. 5.1.2 Immune System Diseases
  4. 5.1.3 Metabolic Diseases
  5. 5.1.4 Other
  6. 5.2 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value by Application
  7. 5.2.1 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value by Application (2021-2032)
  9. 5.2.3 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application (2021-2032)
6 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Regional Value Analysis
  1. 6.1 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value by Region (2021-2032)
  3. 6.2.1 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value by Region: 2021-2026
  4. 6.2.2 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value (2021-2032)
  7. 6.3.2 North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value (2021-2032)
  10. 6.4.2 Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value (2021-2032)
  16. 6.6.2 South America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Country, 2025 VS 2032
7 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Country-level Value Analysis
  1. 7.1 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value by Country (2021-2032)
  3. 7.2.1 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value by Country (2021-2026)
  4. 7.2.2 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Lallemand Health Solutions
  2. 8.1.1 Lallemand Health Solutions Company Information
  3. 8.1.2 Lallemand Health Solutions Business Overview
  4. 8.1.3 Lallemand Health Solutions Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Lallemand Health Solutions Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
  6. 8.1.5 Lallemand Health Solutions Recent Developments
  7. 8.2 Wacker Chemie AG
  8. 8.2.1 Wacker Chemie AG Company Information
  9. 8.2.2 Wacker Chemie AG Business Overview
  10. 8.2.3 Wacker Chemie AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Wacker Chemie AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
  12. 8.2.5 Wacker Chemie AG Recent Developments
  13. 8.3 Biose Industrie
  14. 8.3.1 Biose Industrie Company Information
  15. 8.3.2 Biose Industrie Business Overview
  16. 8.3.3 Biose Industrie Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Biose Industrie Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
  18. 8.3.5 Biose Industrie Recent Developments
  19. 8.4 List Biological Labs, Inc.
  20. 8.4.1 List Biological Labs, Inc. Company Information
  21. 8.4.2 List Biological Labs, Inc. Business Overview
  22. 8.4.3 List Biological Labs, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (2021-2026)
  23. 8.4.4 List Biological Labs, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
  24. 8.4.5 List Biological Labs, Inc. Recent Developments
  25. 8.5 NIZO
  26. 8.5.1 NIZO Company Information
  27. 8.5.2 NIZO Business Overview
  28. 8.5.3 NIZO Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (2021-2026)
  29. 8.5.4 NIZO Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
  30. 8.5.5 NIZO Recent Developments
  31. 8.6 SGS (Quay Pharmaceuticals)
  32. 8.6.1 SGS (Quay Pharmaceuticals) Company Information
  33. 8.6.2 SGS (Quay Pharmaceuticals) Business Overview
  34. 8.6.3 SGS (Quay Pharmaceuticals) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (2021-2026)
  35. 8.6.4 SGS (Quay Pharmaceuticals) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
  36. 8.6.5 SGS (Quay Pharmaceuticals) Recent Developments
  37. 8.7 Assembly Biosciences, Inc.
  38. 8.7.1 Assembly Biosciences, Inc. Company Information
  39. 8.7.2 Assembly Biosciences, Inc. Business Overview
  40. 8.7.3 Assembly Biosciences, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Assembly Biosciences, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
  42. 8.7.5 Assembly Biosciences, Inc. Recent Developments
  43. 8.8 Recipharm (Arranta Bio)
  44. 8.8.1 Recipharm (Arranta Bio) Company Information
  45. 8.8.2 Recipharm (Arranta Bio) Business Overview
  46. 8.8.3 Recipharm (Arranta Bio) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Recipharm (Arranta Bio) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
  48. 8.8.5 Recipharm (Arranta Bio) Recent Developments
  49. 8.9 Bacthera (Novonesis+Lonza)
  50. 8.9.1 Bacthera (Novonesis+Lonza) Company Information
  51. 8.9.2 Bacthera (Novonesis+Lonza) Business Overview
  52. 8.9.3 Bacthera (Novonesis+Lonza) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Bacthera (Novonesis+Lonza) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
  54. 8.9.5 Bacthera (Novonesis+Lonza) Recent Developments
  55. 8.10 Smaltis
  56. 8.10.1 Smaltis Company Information
  57. 8.10.2 Smaltis Business Overview
  58. 8.10.3 Smaltis Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Smaltis Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
  60. 8.10.5 Smaltis Recent Developments
  61. 8.11 Lonza
  62. 8.11.1 Lonza Company Information
  63. 8.11.2 Lonza Business Overview
  64. 8.11.3 Lonza Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Lonza Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
  66. 8.11.5 Lonza Recent Developments
  67. 8.12 vermicon AG
  68. 8.12.1 vermicon AG Company Information
  69. 8.12.2 vermicon AG Business Overview
  70. 8.12.3 vermicon AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (2021-2026)
  71. 8.12.4 vermicon AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
  72. 8.12.5 vermicon AG Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst